Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta

Reuters

Aug 06

<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Inc. has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta $(CHD)$. The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE 3 trial, along with the other trials in the program, is designed to provide supportive data for establishing access and reimbursement in key markets. The results of these trials have not yet been presented. The combination therapy of tobevibart and elebsiran has received several designations from regulatory agencies, highlighting its potential in addressing the unmet medical needs in CHD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806509549) on August 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2557743833"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557743833\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557743833?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557743833","market":"nz","top_or_hot":-1,"title":"Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE 3 trial, along with the other trials in the program, is designed to provide supportive data for establishing access and reimbursement in key markets. The results of these trials have not yet been presented. The combination therapy of tobevibart and elebsiran has received several designations from regulatory agencies, highlighting its potential in addressing the unmet medical needs in CHD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806509549) on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-06 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE 3 trial, along with the other trials in the program, is designed to provide supportive data for establishing access and reimbursement in key markets. The results of these trials have not yet been presented. The combination therapy of tobevibart and elebsiran has received several designations from regulatory agencies, highlighting its potential in addressing the unmet medical needs in CHD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806509549) on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL931KNR:1","article_id":"2557743833","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557743833","pubTimestamp":1754481935,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir Biotechnology Inc. has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta . The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE 3 trial, along with the other trials in the program, is designed to provide supportive data for establishing access and reimbursement in key markets. The results of these trials have not yet been presented. The combination therapy of tobevibart and elebsiran has received several designations from regulatory agencies, highlighting its potential in addressing the unmet medical needs in CHD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4568":"美国抗疫概念","VIR":"Vir Biotechnology, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"Vir Biotechnology在慢性δ型肝炎注册计划中启动ECLIPSE 3试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta\n    \n\n        Vir Biotechnology Inc. has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta $(CHD)$. The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE 3 trial, along with the other trials in the program, is designed to provide supportive data for establishing access and reimbursement in key markets. The results of these trials have not yet been presented. The combination therapy of tobevibart and elebsiran has received several designations from regulatory agencies, highlighting its potential in addressing the unmet medical needs in CHD.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806509549) on August 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}